MedEquities Realty TrustNYSE American: MRT

ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app, today announced that it has appointed Deniz Terlemez as its new Interim Chief Financial Officer (“CFO”), effective November 1, 2024. Deniz Terlemez succeeds Oguz Erkan, the Company's former CFO. Mr. Terlemez served as the Company's Finance Director before his appointment as Interim CFO. “We would like to thank Oguz Erkan for his integral contributions to the.

ISTANBUL--(BUSINESS WIRE)--Türkiye's leading mobility super app Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT) today announced an amendment to extend its share repurchase program. The Company's Board of Directors (the “Board”) authorized a six month extension to its share repurchase program under which the Company may repurchase up to $2.5 million of its outstanding Class A ordinary shares until April 9, 2025. The share repurchase program was originally initiated on Ja.

Marti Technologies, Inc. (NYSE:MRT ) Q2 2024 Earnings Conference Call September 30, 2024 8:30 AM ET Company Participants Oguz Alper Oktem - Founder and Chief Executive Officer Cankut Durgun - Co-Founder and President Conference Call Participants Brett Knoblauch - Cantor Fitzgerald Poe Fratt from - Global Partners Operator Hello, everyone, and thank you for joining us for Marti's First Half 2024 Conference Call. Before we begin, I'd like to mention that today's presentation and earnings release are available on Marti's Investor Relations website at ir.marti.tech.

ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti”) (NYSE American: MRT), Türkiye's leading mobility super app, will announce its 2024 first half financial and operational results before the U.S. markets open on Monday, September 30, 2024. Conference Call and Webcast Details Marti's management will host an analyst and investor conference call and live webcast to discuss its financial and operational results at 3:30 p.m. Istanbul / 1:30 p.m. London / 8:30 a.m. New York time on Monday,.

MRT-6160, a potent and highly selective VAV1-directed molecular glue degrader, represents a potential novel therapeutic approach for systemic and neurological autoimmune and inflammatory diseases Initial Phase 1 clinical results, including biomarker data to demonstrate pharmacodynamic effects, anticipated in Q1 2025 BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the first participants have been dosed in a Phase 1, single ascending dose / multiple ascending dose (SAD/MAD), healthy volunteer study evaluating MRT-6160, a VAV1-directed MGD being developed for systemic and neurological autoimmune diseases. The Company expects to obtain initial data from the Phase 1 study in Q1 2025.

ISTANBUL--(BUSINESS WIRE)--Marti Technologies, Inc. (“Marti” or the “Company”) (NYSE American: MRT), Türkiye's leading mobility super app and only multi-modal urban mobility provider, announced today that as of June 30, 2024, Marti's ride-hailing service has reached over 1,100,000 riders and over 170,000 registered drivers, exceeding the June 30, 2024 targets of over 1,000,000 riders and 165,000 registered drivers. Marti's number of ride-hailing riders grew 121% from December 31, 2023 to June 3.

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

Marti Technologies, Inc. (NYSE American: MRT), Turkey's top mobility super app, is set to release its complete financial and operational outcomes for the year 2023 prior to the opening of U.S. markets on April 16, 2024. A conference call and webcast will be hosted by Marti's management to review the financial results at 3:30 p.m. Istanbul / 1:30 p.m. London / 8:30 a.m. New York time on the same day.